From d1f3ee0ed719a18203299a8b35a9b779aae06782 Mon Sep 17 00:00:00 2001 From: ewollert <35817743+ewollert@users.noreply.github.com> Date: Fri, 3 May 2019 21:04:56 +0200 Subject: [PATCH 1/2] recurate cox2016 --- hbp_knowledge/tau/cox2016.bel | 113 ++++++++++++++++++++++++++-------- 1 file changed, 88 insertions(+), 25 deletions(-) diff --git a/hbp_knowledge/tau/cox2016.bel b/hbp_knowledge/tau/cox2016.bel index 967ba628f..1eb4a650b 100644 --- a/hbp_knowledge/tau/cox2016.bel +++ b/hbp_knowledge/tau/cox2016.bel @@ -77,26 +77,35 @@ SET Citation = {"PubMed", "27574109"} SET Evidence = "Right angle laser light scattering showed significantly greater scattered light intensity in all 4R tau isoforms when compared to 3R isoforms (one-way ANOVA with Holm-Sidak post-hoc, F(5, 18) = 60.22, p < 0.0001; Fig. 2A)" -a(HBP:"3R tau") positiveCorrelation path(MESH:"Protein Aggregation, Pathological") -a(HBP:"4R tau") positiveCorrelation path(MESH:"Protein Aggregation, Pathological") +SET Confidence = "Medium" +a(HBP:"4R tau") -> path(MESH:"Protein Aggregation, Pathological") +UNSET Confidence SET Evidence = "hT40 showed the highest amount of light scattering compared to other 4R isoforms, and there were no differences between the different 3R isoforms" -a(HBP:"Tau isoform F (441 aa)") positiveCorrelation path(MESH:"Protein Aggregation, Pathological") +SET Confidence = "Medium" +a(HBP:"Tau isoform F (441 aa)") -> path(MESH:"Protein Aggregation, Pathological") +UNSET Confidence SET Evidence = "Similar results were seen in the ThS assay, where the 4R isoforms were significantly higher than 3R isoforms (one-way ANOVA with Holm-Sidak post-hoc, F(5, 18) = 19.99, p < 0.0001; Fig. 2B), and no differences were found in comparisons between the individual 4R isoforms or between the 3R isoforms" -a(HBP:"3R tau") positiveCorrelation path(MESH:"Protein Aggregation, Pathological") -a(HBP:"4R tau") positiveCorrelation path(MESH:"Protein Aggregation, Pathological") +SET Confidence = "Medium" +#ThS assay for determination of extent of aggregation +a(HBP:"4R tau") -> path(MESH:"Protein Aggregation, Pathological") +UNSET Confidence SET Evidence = "A mixture of long, intermediate and short filaments, as well as globular oligomers were present in 4R isoform reactions (Fig. 2C–E)" -a(HBP:"4R tau") positiveCorrelation bp(GO:"positive regulation of protein oligomerization") +SET Confidence = "Medium" +a(HBP:"4R tau") -> bp(GO:"positive regulation of protein oligomerization") +UNSET Confidence SET Evidence ="In contrast, 3R isoforms were primarily composed of globular oligomers and only very rare long filaments were found (Fig. 2F–H)" -a(HBP:"3R tau") positiveCorrelation bp(GO:"positive regulation of protein oligomerization") +SET Confidence = "Medium" +a(HBP:"3R tau") -> bp(GO:"positive regulation of protein oligomerization") +UNSET Confidence # PAD exposure (TNT1 reactivity) @@ -105,80 +114,97 @@ than hT24 and hT23 monomers (Kruskal-Wallis ANOVA with Dunn’s post-hoc, H = 18 # Tau isoform D (383 aa): htau24 # Tau isoform C (410 aa): htau39 # Tau isoform Fetal-tau (352 aa): htau23 +SET Confidence = "Low" +#comparison: determination of the levels of PAD exposure a(HBP:"Tau isoform Fetal-tau (352 aa)") -- a(HBP:"phosphatase-activating domain") a(HBP:"Tau isoform D (383 aa)") -- a(HBP:"phosphatase-activating domain") a(HBP:"Tau isoform C (410 aa)") -- a(HBP:"phosphatase-activating domain") +UNSET Confidence SET Evidence = "The hT24 aggregates showed the highest TNT1 signal, which reached significance compared to hT40, hT39, hT37 and hT23 aggregates (one-way ANOVA with Holm-Sidak post-hoc, F(5, 18) = 19.11, p < 0.0001)" # Tau isoform Fetal-tau (352 aa): htau40 # Tau isoform B (381 aa): htau37 +SET Confidence = "Low" +#to discuss: exposure = increase in domain? p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform Fetal-tau (352 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform B (381 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform F (441 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") +UNSET Confidence SET Evidence = "Aggregates of all six tau isoforms showed significant increases in TNT1 reactivity when compared to their respective monomer samples (Fig. 3A; Mann-Whitney test, for all comparisons p = 0.029)" # 6 isoforms: hT40, hT34, hT24, hT39, hT37, hT23 # HBP:"Tau isoform E (412 aa)": htau34 +SET Confidence = "Low" p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform Fetal-tau (352 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform B (381 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform F (441 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform E (412 aa)",pmod(HBP:"protein aggregation")) positiveCorrelation a(HBP:"phosphatase-activating domain") +UNSET Confidence # determine the levels of tau oligomers (TOC1 reactivity) SET Evidence = "Comparisons between isoform monomers showed that hT39 monomer signal was significantly higher than hT24 and hT23 monomers (Kruskal-Wallis ANOVA with Dunn’s post-hoc, H = 18.6, p = 0.0023)" +SET Confidence = "High" a(HBP:"Tau isoform C (410 aa)") -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform D (383 aa)") -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform Fetal-tau (352 aa)") -> a(HBP:"Tau oligomers") +UNSET Confidence SET Evidence = "The hT24 aggregates showed the highest TOC1 signal, which reached significance compared to hT40, hT39, hT37 and hT23 aggregates, while hT34 aggregates were significantly different from hT39, hT37 and hT23 aggregates, and both hT40 and hT39 aggregates are significantly higher than hT37 and hT23 (one-way ANOVA with Holm-Sidak post-hoc, F(5, 18) = 50.77, p < 0.0001)" +SET Confidence = "High" p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform Fetal-tau (352 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform B (381 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform F (441 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform E (412 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") +UNSET Confidence SET Evidence = "Aggregated samples for all six isoforms showed significant increases in TOC1 reactivity when compared to their respective monomer samples (Fig. 3B; Mann-Whitney tests, for all comparisons p = 0.029)" +SET Confidence = "High" p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform Fetal-tau (352 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform B (381 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform F (441 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") p(HBP:"Tau isoform E (412 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") +UNSET Confidence SET Evidence = "As expected, monomer and aggregated samples of all six tau isoforms showed equal reactivity for TNT1 and TOC1 when the samples were denatured because this exposes the epitopes making them equally accessible (Student’s t-tests, for all comparisons p > 0.05; Fig. 3C–H)" +SET Confidence = "High" p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform D (383 aa)") -> a(HBP:"Tau oligomers") -a(HBP:"Tau isoform D (383 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform C (410 aa)") -> a(HBP:"Tau oligomers") -a(HBP:"Tau isoform C (410 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform Fetal-tau (352 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform Fetal-tau (352 aa)") -> a(HBP:"Tau oligomers") -a(HBP:"Tau isoform Fetal-tau (352 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform B (381 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform B (381 aa)") -> a(HBP:"Tau oligomers") -a(HBP:"Tau isoform B (381 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform F (441 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform F (441 aa)") -> a(HBP:"Tau oligomers") -a(HBP:"Tau isoform F (441 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") p(HBP:"Tau isoform E (412 aa)",pmod(HBP:"protein aggregation")) -> a(HBP:"Tau oligomers") a(HBP:"Tau isoform E (412 aa)") -> a(HBP:"Tau oligomers") +SET Confidence = "Low" +a(HBP:"Tau isoform D (383 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") +a(HBP:"Tau isoform C (410 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") +a(HBP:"Tau isoform Fetal-tau (352 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") +a(HBP:"Tau isoform B (381 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") +a(HBP:"Tau isoform F (441 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") a(HBP:"Tau isoform E (412 aa)") positiveCorrelation a(HBP:"phosphatase-activating domain") +UNSET Confidence # effect of isoform-specific tau aggregates on fast axonal transport @@ -186,36 +212,44 @@ SET MeSHAnatomy = {"Axons","Cytoplasm"} SET Evidence = "Perfusion of hT40, hT34 and hT24 aggregates into squid axoplasms significantly impaired anterograde transport (Fig. 4A) when compared to the respective monomers (all at 2 μM)." +SET Confidence = "High" p(HBP:"Tau isoform E (412 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") p(HBP:"Tau isoform F (441 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") +UNSET Confidence SET Evidence = "Similarly, perfusion of squid axoplasms with hT39, hT37 and hT23 aggregates significantly impaired anterograde FAT (Fig. 4A) when compared to the respective monomers (all at 2 μM)" +SET Confidence = "High" p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") p(HBP:"Tau isoform B (381 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") p(HBP:"Tau isoform Fetal-tau (352 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") +UNSET Confidence UNSET MeSHAnatomy SET Evidence = "Pairwise comparisons within tau species showed that hT24 aggregates produced significantly more inhibition of anterograde FAT when compared to hT34 and hT39 aggregates." +SET Confidence = "Medium" p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") -p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") -p(HBP:"Tau isoform E (412 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"anterograde axonal transport") +UNSET Confidence SET Evidence = "hT40, hT34, hT24, hT37 and hT23 aggregates did not significantly impair retrograde FAT when compared to the respective monomers, but hT39 aggregates elicited a mild inhibitory effect on retrograde FAT (Fig. 4B)" +SET Confidence = "High" p(HBP:"Tau isoform C (410 aa)",pmod(HBP:"protein aggregation")) -| bp(GO:"retrograde axonal transport") p(HBP:"Tau isoform F (441 aa)",pmod(HBP:"protein aggregation")) cnc bp(GO:"retrograde axonal transport") p(HBP:"Tau isoform E (412 aa)",pmod(HBP:"protein aggregation")) cnc bp(GO:"retrograde axonal transport") p(HBP:"Tau isoform D (383 aa)",pmod(HBP:"protein aggregation")) cnc bp(GO:"retrograde axonal transport") p(HBP:"Tau isoform B (381 aa)",pmod(HBP:"protein aggregation")) cnc bp(GO:"retrograde axonal transport") p(HBP:"Tau isoform Fetal-tau (352 aa)",pmod(HBP:"protein aggregation")) cnc bp(GO:"retrograde axonal transport") +UNSET Confidence SET Evidence = "Collectively, these studies indicate that inhibition of anterograde FAT represents a toxic effect common to all tau aggregates, regardless of isoform composition" +SET Confidence = "High" a(HBP:"Tau aggregates") -| bp(GO:"anterograde axonal transport") +UNSET Confidence # antibodies: TNT1 (PAD exposure), TOC1 (tau oligomers) and R1 (pan-tau marker) @@ -223,22 +257,30 @@ SET MeSHAnatomy = "Hippocampus" SET Evidence = "Indeed, early pre-tangle neurons within the hippocampus were labeled with all antibodies in Braak I-II cases (Fig. 5A–D)" -a(HBP:pretangles) -- a(HBP:"Tau oligomers") +SET Confidence = "Medium" +a(HBP:pretangles) pos a(HBP:"Tau oligomers") +a(HBP:pretangles) pos p(HGNC:MAPT) +a(HBP:"Braak_Stage I") pos a(HBP:"Tau oligomers") +a(HBP:"Braak_Stage I") pos p(HGNC:MAPT) +a(HBP:"Braak_Stage II") pos a(HBP:"Tau oligomers") +a(HBP:"Braak_Stage II") pos p(HGNC:MAPT) +SET Confidence = "Low" a(HBP:pretangles) -- a(HBP:"phosphatase-activating domain") -a(HBP:pretangles) -- p(HGNC:MAPT) -a(HBP:"Braak_Stage I") -- a(HBP:"Tau oligomers") a(HBP:"Braak_Stage I") -- a(HBP:"phosphatase-activating domain") -a(HBP:"Braak_Stage I") -- p(HGNC:MAPT) -a(HBP:"Braak_Stage II") -- a(HBP:"Tau oligomers") a(HBP:"Braak_Stage II") -- a(HBP:"phosphatase-activating domain") -a(HBP:"Braak_Stage II") -- p(HGNC:MAPT) +UNSET Confidence + + SET Evidence = "In severe AD cases (i.e. Braak stage V-VI), all markers continue to colocalize in classic NFTs within the hippocampus that characterize AD tau pathology (Fig. 5E–H)" +SET Confidence = "High" SET MeSHDisease = "Alzheimer Disease" a(MESH:"Neurofibrillary Tangles") -- a(HBP:"Tau oligomers") -a(MESH:"Neurofibrillary Tangles") -- a(HBP:"phosphatase-activating domain") a(MESH:"Neurofibrillary Tangles") -- p(HGNC:MAPT) +SET Confidence = "Low" +a(MESH:"Neurofibrillary Tangles") -- a(HBP:"phosphatase-activating domain") +UNSET Confidence UNSET MeSHDisease @@ -246,64 +288,85 @@ SET MeSHAnatomy = "Frontal Lobe" SET Evidence = "In CBD, the characteristic astrocytic pathology (e.g. astrocytic plaques) showed extensive co-localization between TNT1, TOC1 and R1 in the frontal cortex (Fig. 5I–L)." +SET Confidence = "High" a(HBP:"Corticobasal Degeneration") -- a(HBP:"Tau oligomers") a(HBP:"Corticobasal Degeneration") -- a(HBP:"phosphatase-activating domain") a(HBP:"Corticobasal Degeneration") -- p(HGNC:MAPT) +UNSET Confidence SET Evidence = "Similarly, the characteristic Pick bodies in the frontal cortex were well labeled by TNT1, TOC1 and R1 in PiD tissue (Fig. 5M–P)" +SET Confidence = "High" SET MeSHDisease = "Pick Disease of the Brain" a(GO:"Pick body") -- a(HBP:"Tau oligomers") a(GO:"Pick body") -- a(HBP:"phosphatase-activating domain") a(GO:"Pick body") -- p(HGNC:MAPT) UNSET MeSHDisease +UNSET Confidence UNSET MeSHAnatomy SET Evidence = "In general, the remarkable co-localization between TNT1, TOC1 and R1 in all tauopathies confirms that PAD exposure and tau oligomerization occur simultaneously in cells displaying tau pathology, irrespective of isoform composition" +SET Confidence = "Medium" path(MESH:Tauopathies) positiveCorrelation a(HBP:"Tau oligomers") -path(MESH:Tauopathies) positiveCorrelation a(HBP:"phosphatase-activating domain") +path(MESH:Tauopathies) -- a(HBP:"phosphatase-activating domain") +UNSET Confidence SET Evidence = "The band patterns in the immunoblots showed that the AD cases contained a mixture of isoforms, the PiD cases clearly contained 3R isoforms but also some 4R isoforms, while the vast majority of pathology in CBD cases were comprised of 4R tau isoforms" +SET Confidence = "High" path(MESH:"Alzheimer Disease") positiveCorrelation a(HBP:"3R tau") path(MESH:"Alzheimer Disease") positiveCorrelation a(HBP:"4R tau") path(MESH:"Pick Disease of the Brain") positiveCorrelation a(HBP:"3R tau") path(MESH:"Pick Disease of the Brain") positiveCorrelation a(HBP:"4R tau") a(HBP:"Corticobasal Degeneration") positiveCorrelation a(HBP:"4R tau") +UNSET Confidence SET Evidence = "Total tau levels in the soluble fractions were similar for AD, CBD and PiD, as indicated by the Tau5 sandwich ELISA (Fig. 6B; one-way ANOVA, F(2,9) = 3.283, p = 0.085)" +SET Confidence = "Low" +#not what said in the evidence path(MESH:"Alzheimer Disease") positiveCorrelation p(HGNC:MAPT) path(MESH:"Pick Disease of the Brain") positiveCorrelation p(HGNC:MAPT) a(HBP:"Corticobasal Degeneration") positiveCorrelation p(HGNC:MAPT) +UNSET Confidence SET Evidence = "In contrast, AD soluble tau displayed the highest level of TNT1 followed by CBD, with PiD having the lowest levels (Fig. 6C; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 24.87, p = 0.0002)." -path(MESH:"Alzheimer Disease") positiveCorrelation a(HBP:"phosphatase-activating domain") -path(MESH:"Pick Disease of the Brain") positiveCorrelation a(HBP:"phosphatase-activating domain") -a(HBP:"Corticobasal Degeneration") positiveCorrelation a(HBP:"phosphatase-activating domain") +SET Confidence = "Medium" +path(MESH:"Alzheimer Disease") -- a(HBP:"phosphatase-activating domain") +path(MESH:"Pick Disease of the Brain") -- a(HBP:"phosphatase-activating domain") +a(HBP:"Corticobasal Degeneration") -- a(HBP:"phosphatase-activating domain") +UNSET Confidence SET Evidence = "Similarly, the soluble fraction from AD contained the greatest level of TOC1 reactivity, followed by CBD and then PiD had the lowest signal (Fig. 6D; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 16.57, p = 0.001)" +SET Confidence = "High" path(MESH:"Alzheimer Disease") positiveCorrelation a(HBP:"Tau oligomers") path(MESH:"Pick Disease of the Brain") positiveCorrelation a(HBP:"Tau oligomers") a(HBP:"Corticobasal Degeneration") positiveCorrelation a(HBP:"Tau oligomers") +UNSET Confidence SET Evidence = "Total tau levels in the insoluble fractions, as detected by Tau5, were highest in AD, followed by CBD and PiD contained the least (Fig. 6E; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 25.93, p = 0.0002)" +SET Confidence = "High" path(MESH:"Alzheimer Disease") positiveCorrelation p(HGNC:MAPT) path(MESH:"Pick Disease of the Brain") positiveCorrelation p(HGNC:MAPT) a(HBP:"Corticobasal Degeneration") positiveCorrelation p(HGNC:MAPT) +UNSET Confidence SET Evidence = "TNT1 detected significantly more PAD exposed tau in AD compared to PiD, and more in CBD when compared to PiD, but AD and CBD were not different (Fig. 6F; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 12.07, p = 0.0028)" +SET Confidence = "Low" path(MESH:"Alzheimer Disease") positiveCorrelation composite(p(HGNC:MAPT),a(HBP:"phosphatase-activating domain")) path(MESH:"Pick Disease of the Brain") positiveCorrelation composite(p(HGNC:MAPT),a(HBP:"phosphatase-activating domain")) a(HBP:"Corticobasal Degeneration") positiveCorrelation composite(p(HGNC:MAPT),a(HBP:"phosphatase-activating domain")) +UNSET Confidence SET Evidence = "TOC1 detected significantly more oligomeric tau in AD compared to CBD and PiD and more in CBD compared to PiD (Fig. 6G; one-way ANOVA with Holm-Sidak post-hoc, F(2,9) = 35.32, p < 0.0001)" +SET Confidence = "High" path(MESH:"Alzheimer Disease") positiveCorrelation a(HBP:"Tau oligomers") path(MESH:"Pick Disease of the Brain") positiveCorrelation a(HBP:"Tau oligomers") a(HBP:"Corticobasal Degeneration") positiveCorrelation a(HBP:"Tau oligomers") +UNSET Confidence From de62eceaa7e2dbe44dde10e7512694faeca16930 Mon Sep 17 00:00:00 2001 From: Charles Tapley Hoyt Date: Sun, 5 May 2019 21:34:39 +0200 Subject: [PATCH 2/2] Update cox2016.bel [skip ci] --- hbp_knowledge/tau/cox2016.bel | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/hbp_knowledge/tau/cox2016.bel b/hbp_knowledge/tau/cox2016.bel index 1eb4a650b..a27608aef 100644 --- a/hbp_knowledge/tau/cox2016.bel +++ b/hbp_knowledge/tau/cox2016.bel @@ -6,8 +6,8 @@ SET DOCUMENT Licenses = "CC BY 4.0" SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de" SET DOCUMENT Name = "Analysis of Isoform-specific Tau Aggregates Suggests a Common Toxic Mechanism Involving Similar Pathological Conformations and Axonal Transport Inhibition" -SET DOCUMENT Version = "1.0.1" -SET DOCUMENT Authors = "Sandra Spalek" +SET DOCUMENT Version = "1.0.2" +SET DOCUMENT Authors = "Sandra Spalek, Esther Wollert" SET DOCUMENT Description = "" ##############